| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Athena Diagostics, Inc. |
| Four Biotech Park 377 Plantation Street, Worcester, CA 01605 * (508) 756-2886 |
| Business Description | The company is a leading commercial diagnostic laboratory focused on performing esoteric tests, which is referd to as assays, primarily in the field of neurology. The company identifies, licenses and commercially develops new esoteric assays and, through their sales force and markets them directly to neurologists. |
|
Filing Information Not yet | ||||
| To Trade As | DXL (NYSE) | Industry | Service (SIC 8071) | |
| Type of Stock Offered | Common Shares | Filing Date | 10/31/2001 | |
| Domestic Shares Filed | 0 | Filing Price | - - | |
| Foreign Shares Filed | 0 | Offering Amount | $119,700,000 | |
| Company Shares | 0 | Est. Expenses | - - | |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - | |
| Being spun off from | Elan Pharmaceuticals, Inc. | |||
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| UBS Warburg LLC | Lead Manager |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 6 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/1998 | 12/31/1999 | 12/31/2000 | 6/30/2000 | 6/30/2001 | ||
| Revenues | - | - | 17.862 | 24.313 | 30.711 | 14.065 | 16.975 |
| Income from Oper. | - | - | 2.424 | 5.460 | 8.431 | 3.405 | 5.155 |
| Net Income | - | - | 1.325 | 3.193 | 5.001 | 2.019 | 3.081 |
| E.P.S | - | - | - | - | - | - | - |
| Revenue Growth (%) | - | - | 36.12 | 26.315 | 20.69 | ||
| Net Income Growth (%) | - | - | 140.98 | 56.62 | 52.60 | ||
| Oper. Profit Margin (%) | - | - | 13.57 | 22.46 | 27.45 | 30.37 | 24.21 |
| Net Profit Margin (%) | - | - | 7.42 | 13.13 | 16.28 | 18.15 | 14.35 |
| Cash Flow - Oper. | 9.96 | 4.18 | 5.14 | ||||
| Cash Flow - Inv. | -1.32 | -0.45 | -0.38 | ||||
| Cash Flow - Fin. | -8.03 | -2.11 | -3.00 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 6/30/2001 | Financial Ratios | ||||
| Total Assets | 33.52 | Current Assets | 11.87 | Current Ratio | 3.34 |
| Total Liab. | 16.69 | Current Liab. | 3.55 | Debt Ratio | 49.80% |
| Total Equity | 16.83 | Working Cap. | 8.32 | Debt to Equity Ratio | 0.99 |
| Cash | 3.49 | Return on Assets | 9.19% | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be distributed to the selling shareholder. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cahill Gordon & Reindel |
| Bank's Law Firm | Dewey Ballantine |
| Auditor | KPMG LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Elan Pharmaceuticals, Inc. | 100.00 | |
| Note: represents ownership of 5% or more prior to the offering. | ||